Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2020-07-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
반기보고서 (2020.05)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Hyundai Pharm Co., Ltd. for the period ending May 31, 2020. It contains detailed financial data, business operations, management discussions, and organizational information, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full content of the report itself. H1 2020
2020-07-15 Korean
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Hyundai Pharm Co., Ltd. regarding the extension of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This type of filing specifically details the company's decision to buy back its own shares through a trust, which falls under the category of 'Transaction in Own Shares'.
2020-07-13 Korean
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities regarding a decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). It details the contract terms, board resolution dates, and financial limits for share buybacks. This falls under the category of a company reporting its own share transactions/repurchase activities.
2020-06-26 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Hyundai Pharm. It details specific transactions (sales) of shares by individuals and entities related to the major shareholders. This type of filing is a standard regulatory disclosure regarding changes in significant share ownership levels, which falls under the 'Major Shareholding Notification' category.
2020-06-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large-Scale Shareholdings' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. This document is a standard regulatory filing used to disclose changes in significant share ownership (crossing the 5% threshold or subsequent changes). Based on the provided filing categories, this corresponds to a 'Major Shareholding Notification'.
2020-06-12 Korean
투자판단관련주요경영사항
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Hyundai Pharm regarding a 'Technology Transfer Agreement' (licensing deal) for a diabetes drug. It details the contract terms, financial milestones, and counterparty information. Since this is a specific corporate event announcement regarding a business transaction (licensing/M&A-related activity) and does not fit into specific categories like 'M&A' (which usually implies full company takeovers) or 'Financial Reports', it is best classified as a general regulatory filing (RNS) under the provided schema.
2020-05-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.